Low Plasma Levels of Soluble Endoglin and Cardiovascular Events in Patients Undergoing Coronary Angiography

• Published in: Biomedicines Vol. 11; no. 11; p. 2975
• Main Authors: Saita, Emi, Kishimoto, Yoshimi, Aoyama, Masayuki, Ohmori, Reiko, Kondo, Kazuo, Momiyama, Yukihiko
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-11-2023
• Subjects: Angina; Angina pectoris; Angiography; Arteriosclerosis; Atherosclerosis; biomarker; Cardiac patients; Cardiovascular disease; Cardiovascular diseases; cardiovascular events; Cell membranes; Cerebral infarction; Congestive heart failure; Coronary artery bypass; Coronary artery disease; Coronary vessels; Endoglin; Ethylenediaminetetraacetic acid; Heart attack; Heart attacks; Heart diseases; Heart failure; Medical imaging; Myocardial infarction; Plasma; Plasma levels; Transforming growth factor-b; Transforming growth factors; Japan
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11112975

TGF-β is recognized as playing a protective role against atherosclerosis. Endoglin is a receptor for TGF-β, and its expression is upregulated in atherosclerotic plaques. Endoglin is secreted from the cell membrane into the circulation as a soluble form (sEng). We previously reported that plasma sEng levels were low in patients with coronary artery disease (CAD). However, the prognostic value of sEng levels has not been clarified. We investigated the association between plasma sEng levels and cardiovascular events in 403 patients who had an elective coronary angiography and were then followed up. Cardiovascular events were defined as cardiovascular death, myocardial infarction, unstable angina, heart failure, stroke, or coronary revascularization. Of the 403 patients, 209 (52%) had CAD. Plasma sEng levels were lower in patients with CAD than in those without CAD (median 4.26 vs. 4.41 ng/mL, p < 0.025). During a mean follow-up period of 7.5 ± 4.5 years, cardiovascular events occurred in 79 patients. Compared with 324 patients without events, 79 with events had lower sEng levels (3.95 vs. 4.39 ng/mL) and more often had an sEng level < 3.9 ng/mL (47% vs. 28%) (p < 0.02). A Kaplan–Meier analysis showed lower event-free survival in patients with sEng < 3.9 ng/mL than in those with ≥3.9 ng/mL (p < 0.02). In a multivariate Cox proportional hazards analysis, the sEng level (<3.9 ng/mL) was an independent predictor of cardiovascular events (hazard ratio: 1.59; 95%CI: 1.01–2.49). Furthermore, only among the 209 patients with CAD, the sEng level was also a predictor of further cardiovascular events (hazard ratio: 2.07; 95%CI: 1.24–3.45). Thus, low plasma sEng levels were found to be associated with an increased risk of cardiovascular events in patients with CAD and patients undergoing coronary angiography.